How behavioral segmentation is driving pharma’s digital evolution

Behavioral segmentation is the practice of categorizing users based on their behaviors, preferences, and motivations. Within pharma, it not only enhances product development but also supports personalization in communication and the patients’ treatment journeys, ensuring a smoother dialogue with end users. This enables solutions that are more relevant, impactful, and equitable—ultimately delivering better experiences and outcomes.

Traditionally, pharmaceutical companies have relied on segmentation methods rooted in therapeutic areas (TAs), treatment pathways, and demographic data. While these approaches provide insights into clinical and medical needs, they often fail to capture the nuances of patient behavior. This can lead to generalized solutions that unintentionally reinforce biases or stigmatize certain patient groups.

For instance, treating Type 1 and Type 2 diabetes as entirely separate cohorts overlooks shared behavioral patterns that could inform better, more inclusive design.

Behavioral segmentation offers a powerful way to address these challenges. Unlike traditional demographic or psychographic segmentation, behavioral segmentation focuses on what users do rather than just who they are or what they say they value.

Moving away from classic medical segmentation models to behavioral segmentation is a significant shift for pharmaceutical companies. It requires them to move away from a solely product-centric approach and think more like consumer brands that prioritize customer experience and satisfaction. For large pharmaceutical companies, this transition can be challenging for several reasons:

1. Complexity of human behavior: Human behavior is inherently complex and influenced by numerous factors, including cultural, psychological, and social elements. Understanding these intricacies requires a deep and ongoing investment in research and data analysis.

2. Organizational inertia: Large pharma companies often face organizational inertia, where established structures and processes are geared towards product development and regulatory compliance rather than consumer engagement. Shifting to a consumer-centric model demands new skills, technologies, and, often, a cultural transformation.

3. Data privacy and trust: While collecting behavioral data is critical for effective segmentation, pharma companies must also navigate strict regulations around data privacy and build consumer trust. Patients must feel confident that their data will be used responsibly and ethically.

Of course, behavioral segmentation isn't a silver bullet. The pharmaceutical industry is navigating an era of profound change, driven by technological advancements, regulatory shifts, and increasing pressure to deliver patient-centric care. While designing exceptional user experiences is a cornerstone of success, it’s only one piece of a larger puzzle.

True digital transformation requires not just better tools and interfaces, but a rethinking of how organizations operate. This means aligning cross-functional teams, fostering a culture of innovation, and implementing scalable processes that integrate design thinking and user research into every stage of product development. Without this foundational shift, even the most sophisticated behavioral segmentation efforts will struggle to deliver meaningful results.

Many pharmaceutical companies face the challenge of balancing these strategic imperatives. Digital health initiatives often suffer from siloed approaches, where product teams prioritize technical feasibility or compliance over user needs.

This disconnect can result in digital products that fail to resonate with their intended audiences, leading to low adoption rates and missed opportunities for impact.

To capitalize on behavioral segmentation, companies must ensure that insights are not confined to individual product design teams. Behavioral data should become a shared asset across the organization, driving better decision-making at all levels.

Leveraging technologies like AI can significantly increase the speed and efficiency of data analysis, allowing companies to rapidly translate insights into actionable strategies.

For example, AI-powered platforms can synthesize user behavior data, making it accessible and understandable to stakeholders beyond the design team.

At Manyone, we are starting to implement AI tools that help pharma companies accomplish this. This democratization of insights ensures that behavioral data informs everything from marketing strategies to clinical support services, creating a unified approach to addressing patient needs.

Companies that combine organizational transformation with robust behavioral design gain a significant advantage. Success isn’t about being first to market—it’s about being the best. By focusing on deep user understanding and aligning operations around patient needs, organizations can create products that truly stand out.

As digital health evolves, companies adopting behavioral segmentation will lead innovation and redefine patient engagement. By embedding this approach into their core strategies, they can thrive in an increasingly consumer-driven healthcare ecosystem, delivering better outcomes and lasting impact.

Join our upcoming event in Copenhagen on digital health.